Literature DB >> 29282306

Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j.

Sol Y Nuñez1, Andrea Ziblat1, Florencia Secchiari1, Nicolás I Torres1, Jessica M Sierra1, Ximena L Raffo Iraolagoitia1, Romina E Araya1, Carolina I Domaica1, Mercedes B Fuertes1, Norberto W Zwirner2,3.   

Abstract

NK cells play important roles during immunosurveillance against tumors and viruses as they trigger cytotoxicity against susceptible cells and secrete proinflammatory cytokines such as IFN-γ. In addition, upon activation, macrophages can become proinflammatory (M1) or anti-inflammatory (M2) cells. Although the consequences of the cross-talk between M1 and NK cells are known, the outcome of the cross-talk between M2 and NK cells remains ill-defined. Therefore, in the current work, we investigated the outcome and the underlying mechanisms of the interaction between resting or stimulated human NK cells with M1 or M2. We observed a lower percentage of activated NK cells that produced less IFN-γ upon coculture with M2. Also, CD56dim NK cells cocultured with M2 displayed lower degranulation and cytotoxic activity than NK cells cocultured with M1. Soluble TGF-β and M2-driven upregulation of CD85j (ILT-2) on NK cells accounted for the diminished IFN-γ production by CD56bright NK cells, whereas M2-driven upregulation of CD85j on NK cells accounted for the generation of hyporesponsive CD56dim NK cells with limited degranulation and cytotoxic capacity. Accordingly, M2 expressed higher amounts of HLA-G, the main ligand for CD85j, than M1. Hyporesponsiveness to degranulation in NK cells was not restored at least for several hours upon removal of M2. Therefore, alternatively activated macrophages restrain NK cell activation and effector functions through different mechanisms, leading to NK cells that display diminished IFN-γ production and at least a transiently impaired degranulation ability. These results unravel an inhibitory circuit of possible relevance in pathological situations.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29282306     DOI: 10.4049/jimmunol.1700737

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer.

Authors:  Spas Dimitrov Markov; Thomas C Caffrey; Kelly A O'Connell; James A Grunkemeyer; Simon Shin; Ryan Hanson; Prathamesh P Patil; Surendra K Shukla; Daisy Gonzalez; Ayrianne J Crawford; Krysten E Vance; Ying Huang; Kirsten C Eberle; Prakash Radhakrishnan; Paul M Grandgenett; Pankaj K Singh; Ragupathy Madiyalakan; Tracy R Daniels-Wells; Manuel L Penichet; Christopher F Nicodemus; Jill A Poole; Elizabeth M Jaffee; Michael A Hollingsworth; Kamiya Mehla
Journal:  Mol Cancer Ther       Date:  2021-10-08       Impact factor: 6.009

2.  Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer.

Authors:  Carino Gurjao; David Liu; Matan Hofree; Saud H AlDubayan; Isaac Wakiro; Mei-Ju Su; Kristen Felt; Evisa Gjini; Lauren K Brais; Asaf Rotem; Michael H Rosenthal; Orit Rozenblatt-Rosen; Scott Rodig; Kimmie Ng; Eliezer M Van Allen; Steven M Corsello; Shuji Ogino; Aviv Regev; Jonathan A Nowak; Marios Giannakis
Journal:  Cancer Immunol Res       Date:  2019-06-19       Impact factor: 11.151

3.  M2 macrophages are closely associated with accelerated clavicle fracture healing in patients with traumatic brain injury: a retrospective cohort study.

Authors:  Ran Zhang; Yi Liang; Shuxiang Wei
Journal:  J Orthop Surg Res       Date:  2018-08-29       Impact factor: 2.359

4.  Clinical Significance of Potential Unidentified HLA-G Isoforms Without α1 Domain but Containing Intron 4 in Colorectal Cancer Patients.

Authors:  Aifen Lin; Xia Zhang; Rui-Li Zhang; Jian-Gang Zhang; Wen-Jun Zhou; Wei-Hua Yan
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

5.  Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity.

Authors:  Kun He; Shengguo Jia; Yue Lou; Ping Liu; Lisa X Xu
Journal:  Cell Death Dis       Date:  2019-03-04       Impact factor: 8.469

Review 6.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

7.  Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1.

Authors:  Andrea Ziblat; Ximena Lucía Raffo Iraolagoitia; Sol Yanel Nuñez; Nicolás Ignacio Torres; Florencia Secchiari; Jessica Mariel Sierra; Raúl Germán Spallanzani; Agustín Rovegno; Fernando Pablo Secin; Mercedes Beatriz Fuertes; Carolina Inés Domaica; Norberto Walter Zwirner
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

8.  Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.

Authors:  Qing Wei Winnie Choo; Ricky Abdi Gunawan Koean; Shu-Chun Chang; Wee Joo Chng; Ming Chun Chan; Wilson Wang; Jun Zhi Er; Jeak Ling Ding
Journal:  Immunol Cell Biol       Date:  2020-01-13       Impact factor: 5.126

9.  Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma.

Authors:  Hong Kwan Kim; Je-Gun Joung; Yoon-La Choi; Se-Hoon Lee; Byung Jo Park; Yong Soo Choi; Daeun Ryu; Jae-Yong Nam; Mi-Sook Lee; Woong-Yang Park; Soohyun Hwang; Hongui Cha; Hong Sook Kim; Sanghyuk Lee; Yeonjoo Jung; Jong Eun Lee; Junsang Doh; Soonmyung Paik; Jung Hee Kang; Jinseon Lee; Jhingook Kim
Journal:  iScience       Date:  2020-07-18

Review 10.  HLA-G Expressing Immune Cells in Immune Mediated Diseases.

Authors:  P Contini; Giuseppe Murdaca; Francesco Puppo; Simone Negrini
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.